nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—lung cancer—liver cancer	0.821	1	CtDrD
Pemetrexed—Interstitial pneumonia—Sorafenib—liver cancer	0.00203	0.0188	CcSEcCtD
Pemetrexed—Peripheral motor neuropathy—Epirubicin—liver cancer	0.00199	0.0184	CcSEcCtD
Pemetrexed—Transient ischaemic attack—Sorafenib—liver cancer	0.00194	0.018	CcSEcCtD
Pemetrexed—Peripheral motor neuropathy—Doxorubicin—liver cancer	0.00184	0.017	CcSEcCtD
Pemetrexed—Mucosal inflammation—Sorafenib—liver cancer	0.00177	0.0164	CcSEcCtD
Pemetrexed—Embolism—Sorafenib—liver cancer	0.00153	0.0142	CcSEcCtD
Pemetrexed—Haemoglobin decreased—Sorafenib—liver cancer	0.00143	0.0132	CcSEcCtD
Pemetrexed—Interstitial lung disease—Sorafenib—liver cancer	0.00139	0.0128	CcSEcCtD
Pemetrexed—Peripheral sensory neuropathy—Epirubicin—liver cancer	0.00127	0.0118	CcSEcCtD
Pemetrexed—Myocardial ischaemia—Sorafenib—liver cancer	0.00122	0.0113	CcSEcCtD
Pemetrexed—Peripheral sensory neuropathy—Doxorubicin—liver cancer	0.00117	0.0109	CcSEcCtD
Pemetrexed—Neoplasm malignant—Sorafenib—liver cancer	0.00115	0.0106	CcSEcCtD
Pemetrexed—DCK—Doxorubicin—Epirubicin—liver cancer	0.00115	0.519	CbGdCrCtD
Pemetrexed—DCK—Epirubicin—Doxorubicin—liver cancer	0.00106	0.481	CbGdCrCtD
Pemetrexed—Skin exfoliation—Sorafenib—liver cancer	0.000937	0.00868	CcSEcCtD
Pemetrexed—Neuropathy—Sorafenib—liver cancer	0.000921	0.00854	CcSEcCtD
Pemetrexed—Tetrahydrofolic acid—MTHFR—liver cancer	0.000804	0.284	CrCbGaD
Pemetrexed—Folic Acid—MTHFR—liver cancer	0.000804	0.284	CrCbGaD
Pemetrexed—Renal failure acute—Sorafenib—liver cancer	0.000771	0.00715	CcSEcCtD
Pemetrexed—Mood swings—Sorafenib—liver cancer	0.000675	0.00625	CcSEcCtD
Pemetrexed—Dehydration—Sorafenib—liver cancer	0.000662	0.00614	CcSEcCtD
Pemetrexed—Mucosal inflammation—Epirubicin—liver cancer	0.000655	0.00607	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.000641	0.00594	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.000641	0.00594	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Sorafenib—liver cancer	0.000628	0.00582	CcSEcCtD
Pemetrexed—Dysphagia—Sorafenib—liver cancer	0.000616	0.0057	CcSEcCtD
Pemetrexed—Mucosal inflammation—Doxorubicin—liver cancer	0.000606	0.00561	CcSEcCtD
Pemetrexed—Pancreatitis—Sorafenib—liver cancer	0.000604	0.00559	CcSEcCtD
Pemetrexed—Febrile neutropenia—Epirubicin—liver cancer	0.000603	0.00558	CcSEcCtD
Pemetrexed—Neutropenia—Sorafenib—liver cancer	0.000576	0.00533	CcSEcCtD
Pemetrexed—Embolism—Epirubicin—liver cancer	0.000565	0.00523	CcSEcCtD
Pemetrexed—Febrile neutropenia—Doxorubicin—liver cancer	0.000558	0.00517	CcSEcCtD
Pemetrexed—Methotrexate—MTHFR—liver cancer	0.00055	0.194	CrCbGaD
Pemetrexed—Infestation NOS—Sorafenib—liver cancer	0.000549	0.00509	CcSEcCtD
Pemetrexed—Infestation—Sorafenib—liver cancer	0.000549	0.00509	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.000544	0.00504	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Sorafenib—liver cancer	0.000541	0.00501	CcSEcCtD
Pemetrexed—Renal failure—Sorafenib—liver cancer	0.00054	0.005	CcSEcCtD
Pemetrexed—Myocardial infarction—Sorafenib—liver cancer	0.000538	0.00499	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Sorafenib—liver cancer	0.000538	0.00499	CcSEcCtD
Pemetrexed—Stomatitis—Sorafenib—liver cancer	0.000535	0.00496	CcSEcCtD
Pemetrexed—Embolism—Doxorubicin—liver cancer	0.000523	0.00484	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Sorafenib—liver cancer	0.000519	0.00481	CcSEcCtD
Pemetrexed—Thrombosis—Epirubicin—liver cancer	0.000512	0.00475	CcSEcCtD
Pemetrexed—Folic Acid—CYP2E1—liver cancer	0.000489	0.173	CrCbGaD
Pemetrexed—Urinary tract disorder—Sorafenib—liver cancer	0.000487	0.00451	CcSEcCtD
Pemetrexed—Neuritis—Epirubicin—liver cancer	0.000486	0.0045	CcSEcCtD
Pemetrexed—Urethral disorder—Sorafenib—liver cancer	0.000483	0.00448	CcSEcCtD
Pemetrexed—Thrombosis—Doxorubicin—liver cancer	0.000474	0.00439	CcSEcCtD
Pemetrexed—Erythema multiforme—Sorafenib—liver cancer	0.000466	0.00432	CcSEcCtD
Pemetrexed—Neuritis—Doxorubicin—liver cancer	0.000449	0.00416	CcSEcCtD
Pemetrexed—Arrhythmia—Sorafenib—liver cancer	0.00044	0.00408	CcSEcCtD
Pemetrexed—Alopecia—Sorafenib—liver cancer	0.000435	0.00403	CcSEcCtD
Pemetrexed—Erythema—Sorafenib—liver cancer	0.000429	0.00397	CcSEcCtD
Pemetrexed—Malnutrition—Sorafenib—liver cancer	0.000429	0.00397	CcSEcCtD
Pemetrexed—Neoplasm malignant—Epirubicin—liver cancer	0.000425	0.00393	CcSEcCtD
Pemetrexed—Dysgeusia—Sorafenib—liver cancer	0.00042	0.00389	CcSEcCtD
Pemetrexed—Rectal haemorrhage—Epirubicin—liver cancer	0.000401	0.00372	CcSEcCtD
Pemetrexed—Anaemia—Sorafenib—liver cancer	0.000396	0.00367	CcSEcCtD
Pemetrexed—Lacrimation increased—Epirubicin—liver cancer	0.000393	0.00365	CcSEcCtD
Pemetrexed—Neoplasm malignant—Doxorubicin—liver cancer	0.000393	0.00364	CcSEcCtD
Pemetrexed—Syncope—Sorafenib—liver cancer	0.000385	0.00356	CcSEcCtD
Pemetrexed—Leukopenia—Sorafenib—liver cancer	0.000384	0.00356	CcSEcCtD
Pemetrexed—Creatinine increased—Epirubicin—liver cancer	0.000381	0.00353	CcSEcCtD
Pemetrexed—Loss of consciousness—Sorafenib—liver cancer	0.000377	0.00349	CcSEcCtD
Pemetrexed—Rectal haemorrhage—Doxorubicin—liver cancer	0.000371	0.00344	CcSEcCtD
Pemetrexed—Hypertension—Sorafenib—liver cancer	0.00037	0.00343	CcSEcCtD
Pemetrexed—Myalgia—Sorafenib—liver cancer	0.000365	0.00338	CcSEcCtD
Pemetrexed—Arthralgia—Sorafenib—liver cancer	0.000365	0.00338	CcSEcCtD
Pemetrexed—Lacrimation increased—Doxorubicin—liver cancer	0.000364	0.00337	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000363	0.00336	CcSEcCtD
Pemetrexed—Pulmonary embolism—Epirubicin—liver cancer	0.000363	0.00336	CcSEcCtD
Pemetrexed—Ventricular tachycardia—Epirubicin—liver cancer	0.000363	0.00336	CcSEcCtD
Pemetrexed—Creatinine increased—Doxorubicin—liver cancer	0.000352	0.00327	CcSEcCtD
Pemetrexed—Anaphylactic shock—Sorafenib—liver cancer	0.00035	0.00324	CcSEcCtD
Pemetrexed—Colitis—Epirubicin—liver cancer	0.000348	0.00323	CcSEcCtD
Pemetrexed—Infection—Sorafenib—liver cancer	0.000348	0.00322	CcSEcCtD
Pemetrexed—Skin exfoliation—Epirubicin—liver cancer	0.000346	0.00321	CcSEcCtD
Pemetrexed—Shock—Sorafenib—liver cancer	0.000344	0.00319	CcSEcCtD
Pemetrexed—Nervous system disorder—Sorafenib—liver cancer	0.000343	0.00318	CcSEcCtD
Pemetrexed—Thrombocytopenia—Sorafenib—liver cancer	0.000343	0.00318	CcSEcCtD
Pemetrexed—Neuropathy—Epirubicin—liver cancer	0.00034	0.00315	CcSEcCtD
Pemetrexed—Skin disorder—Sorafenib—liver cancer	0.00034	0.00315	CcSEcCtD
Pemetrexed—Pulmonary embolism—Doxorubicin—liver cancer	0.000336	0.00311	CcSEcCtD
Pemetrexed—Ventricular tachycardia—Doxorubicin—liver cancer	0.000336	0.00311	CcSEcCtD
Pemetrexed—Anorexia—Sorafenib—liver cancer	0.000334	0.00309	CcSEcCtD
Pemetrexed—Oesophagitis—Epirubicin—liver cancer	0.000331	0.00307	CcSEcCtD
Pemetrexed—Colitis—Doxorubicin—liver cancer	0.000322	0.00298	CcSEcCtD
Pemetrexed—Skin exfoliation—Doxorubicin—liver cancer	0.00032	0.00297	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000319	0.00296	CcSEcCtD
Pemetrexed—Neuropathy—Doxorubicin—liver cancer	0.000315	0.00292	CcSEcCtD
Pemetrexed—Sepsis—Epirubicin—liver cancer	0.000315	0.00292	CcSEcCtD
Pemetrexed—Dyspnoea—Sorafenib—liver cancer	0.000312	0.00289	CcSEcCtD
Pemetrexed—Dyspepsia—Sorafenib—liver cancer	0.000308	0.00286	CcSEcCtD
Pemetrexed—Oesophagitis—Doxorubicin—liver cancer	0.000307	0.00284	CcSEcCtD
Pemetrexed—Decreased appetite—Sorafenib—liver cancer	0.000304	0.00282	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Sorafenib—liver cancer	0.000302	0.0028	CcSEcCtD
Pemetrexed—Fatigue—Sorafenib—liver cancer	0.000302	0.0028	CcSEcCtD
Pemetrexed—Pain—Sorafenib—liver cancer	0.000299	0.00277	CcSEcCtD
Pemetrexed—Constipation—Sorafenib—liver cancer	0.000299	0.00277	CcSEcCtD
Pemetrexed—Sepsis—Doxorubicin—liver cancer	0.000291	0.0027	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Sorafenib—liver cancer	0.000286	0.00265	CcSEcCtD
Pemetrexed—Renal failure acute—Epirubicin—liver cancer	0.000285	0.00264	CcSEcCtD
Pemetrexed—Urticaria—Sorafenib—liver cancer	0.000278	0.00258	CcSEcCtD
Pemetrexed—Abdominal pain—Sorafenib—liver cancer	0.000277	0.00256	CcSEcCtD
Pemetrexed—Body temperature increased—Sorafenib—liver cancer	0.000277	0.00256	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Epirubicin—liver cancer	0.000269	0.00249	CcSEcCtD
Pemetrexed—Renal failure acute—Doxorubicin—liver cancer	0.000264	0.00244	CcSEcCtD
Pemetrexed—Hypersensitivity—Sorafenib—liver cancer	0.000258	0.00239	CcSEcCtD
Pemetrexed—Asthenia—Sorafenib—liver cancer	0.000251	0.00233	CcSEcCtD
Pemetrexed—Mood swings—Epirubicin—liver cancer	0.000249	0.00231	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Doxorubicin—liver cancer	0.000249	0.0023	CcSEcCtD
Pemetrexed—Pruritus—Sorafenib—liver cancer	0.000248	0.00229	CcSEcCtD
Pemetrexed—Blood creatinine increased—Epirubicin—liver cancer	0.000247	0.00228	CcSEcCtD
Pemetrexed—Dehydration—Epirubicin—liver cancer	0.000245	0.00227	CcSEcCtD
Pemetrexed—Diarrhoea—Sorafenib—liver cancer	0.00024	0.00222	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000237	0.0022	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000237	0.0022	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000232	0.00215	CcSEcCtD
Pemetrexed—Dizziness—Sorafenib—liver cancer	0.000232	0.00214	CcSEcCtD
Pemetrexed—Mood swings—Doxorubicin—liver cancer	0.000231	0.00214	CcSEcCtD
Pemetrexed—Blood creatinine increased—Doxorubicin—liver cancer	0.000228	0.00211	CcSEcCtD
Pemetrexed—Dysphagia—Epirubicin—liver cancer	0.000228	0.00211	CcSEcCtD
Pemetrexed—Dehydration—Doxorubicin—liver cancer	0.000227	0.0021	CcSEcCtD
Pemetrexed—Pancreatitis—Epirubicin—liver cancer	0.000223	0.00207	CcSEcCtD
Pemetrexed—Vomiting—Sorafenib—liver cancer	0.000223	0.00206	CcSEcCtD
Pemetrexed—Angina pectoris—Epirubicin—liver cancer	0.000222	0.00205	CcSEcCtD
Pemetrexed—Rash—Sorafenib—liver cancer	0.000221	0.00205	CcSEcCtD
Pemetrexed—Dermatitis—Sorafenib—liver cancer	0.000221	0.00204	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000219	0.00203	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000219	0.00203	CcSEcCtD
Pemetrexed—Pancytopenia—Epirubicin—liver cancer	0.000216	0.002	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000215	0.00199	CcSEcCtD
Pemetrexed—Neutropenia—Epirubicin—liver cancer	0.000213	0.00197	CcSEcCtD
Pemetrexed—Dysphagia—Doxorubicin—liver cancer	0.000211	0.00195	CcSEcCtD
Pemetrexed—Nausea—Sorafenib—liver cancer	0.000208	0.00193	CcSEcCtD
Pemetrexed—Pancreatitis—Doxorubicin—liver cancer	0.000206	0.00191	CcSEcCtD
Pemetrexed—Angina pectoris—Doxorubicin—liver cancer	0.000205	0.0019	CcSEcCtD
Pemetrexed—Infestation NOS—Epirubicin—liver cancer	0.000203	0.00188	CcSEcCtD
Pemetrexed—Infestation—Epirubicin—liver cancer	0.000203	0.00188	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000201	0.00186	CcSEcCtD
Pemetrexed—Pancytopenia—Doxorubicin—liver cancer	0.0002	0.00185	CcSEcCtD
Pemetrexed—Renal failure—Epirubicin—liver cancer	0.000199	0.00185	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Epirubicin—liver cancer	0.000199	0.00184	CcSEcCtD
Pemetrexed—Stomatitis—Epirubicin—liver cancer	0.000198	0.00183	CcSEcCtD
Pemetrexed—Conjunctivitis—Epirubicin—liver cancer	0.000197	0.00183	CcSEcCtD
Pemetrexed—Neutropenia—Doxorubicin—liver cancer	0.000197	0.00182	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Epirubicin—liver cancer	0.000192	0.00178	CcSEcCtD
Pemetrexed—Agranulocytosis—Epirubicin—liver cancer	0.000189	0.00175	CcSEcCtD
Pemetrexed—Infestation NOS—Doxorubicin—liver cancer	0.000188	0.00174	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—liver cancer	0.000188	0.00174	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000186	0.00172	CcSEcCtD
Pemetrexed—Renal failure—Doxorubicin—liver cancer	0.000185	0.00171	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Doxorubicin—liver cancer	0.000184	0.0017	CcSEcCtD
Pemetrexed—Methotrexate—ALB—liver cancer	0.000184	0.0649	CrCbGaD
Pemetrexed—Stomatitis—Doxorubicin—liver cancer	0.000183	0.0017	CcSEcCtD
Pemetrexed—Conjunctivitis—Doxorubicin—liver cancer	0.000182	0.00169	CcSEcCtD
Pemetrexed—Hepatitis—Epirubicin—liver cancer	0.000182	0.00169	CcSEcCtD
Pemetrexed—Pharyngitis—Epirubicin—liver cancer	0.000181	0.00167	CcSEcCtD
Pemetrexed—Urinary tract disorder—Epirubicin—liver cancer	0.00018	0.00167	CcSEcCtD
Pemetrexed—Urethral disorder—Epirubicin—liver cancer	0.000179	0.00165	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Doxorubicin—liver cancer	0.000178	0.00164	CcSEcCtD
Pemetrexed—Agranulocytosis—Doxorubicin—liver cancer	0.000175	0.00162	CcSEcCtD
Pemetrexed—Erythema multiforme—Epirubicin—liver cancer	0.000172	0.0016	CcSEcCtD
Pemetrexed—Eye disorder—Epirubicin—liver cancer	0.00017	0.00158	CcSEcCtD
Pemetrexed—Hepatitis—Doxorubicin—liver cancer	0.000168	0.00156	CcSEcCtD
Pemetrexed—Pharyngitis—Doxorubicin—liver cancer	0.000167	0.00155	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—liver cancer	0.000166	0.00154	CcSEcCtD
Pemetrexed—Urethral disorder—Doxorubicin—liver cancer	0.000165	0.00153	CcSEcCtD
Pemetrexed—Arrhythmia—Epirubicin—liver cancer	0.000163	0.00151	CcSEcCtD
Pemetrexed—Alopecia—Epirubicin—liver cancer	0.000161	0.00149	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—liver cancer	0.000159	0.00148	CcSEcCtD
Pemetrexed—Erythema—Epirubicin—liver cancer	0.000159	0.00147	CcSEcCtD
Pemetrexed—Malnutrition—Epirubicin—liver cancer	0.000159	0.00147	CcSEcCtD
Pemetrexed—Eye disorder—Doxorubicin—liver cancer	0.000157	0.00146	CcSEcCtD
Pemetrexed—Dysgeusia—Epirubicin—liver cancer	0.000155	0.00144	CcSEcCtD
Pemetrexed—Arrhythmia—Doxorubicin—liver cancer	0.000151	0.00139	CcSEcCtD
Pemetrexed—Alopecia—Doxorubicin—liver cancer	0.000149	0.00138	CcSEcCtD
Pemetrexed—Malnutrition—Doxorubicin—liver cancer	0.000147	0.00136	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—liver cancer	0.000147	0.00136	CcSEcCtD
Pemetrexed—Anaemia—Epirubicin—liver cancer	0.000147	0.00136	CcSEcCtD
Pemetrexed—Dysgeusia—Doxorubicin—liver cancer	0.000144	0.00133	CcSEcCtD
Pemetrexed—Syncope—Epirubicin—liver cancer	0.000142	0.00132	CcSEcCtD
Pemetrexed—Leukopenia—Epirubicin—liver cancer	0.000142	0.00131	CcSEcCtD
Pemetrexed—Loss of consciousness—Epirubicin—liver cancer	0.000139	0.00129	CcSEcCtD
Pemetrexed—Hypertension—Epirubicin—liver cancer	0.000137	0.00127	CcSEcCtD
Pemetrexed—Anaemia—Doxorubicin—liver cancer	0.000136	0.00126	CcSEcCtD
Pemetrexed—Arthralgia—Epirubicin—liver cancer	0.000135	0.00125	CcSEcCtD
Pemetrexed—Myalgia—Epirubicin—liver cancer	0.000135	0.00125	CcSEcCtD
Pemetrexed—Chest pain—Epirubicin—liver cancer	0.000135	0.00125	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000134	0.00124	CcSEcCtD
Pemetrexed—Syncope—Doxorubicin—liver cancer	0.000132	0.00122	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—liver cancer	0.000131	0.00122	CcSEcCtD
Pemetrexed—Anaphylactic shock—Epirubicin—liver cancer	0.000129	0.0012	CcSEcCtD
Pemetrexed—Oedema—Epirubicin—liver cancer	0.000129	0.0012	CcSEcCtD
Pemetrexed—Loss of consciousness—Doxorubicin—liver cancer	0.000129	0.00119	CcSEcCtD
Pemetrexed—Infection—Epirubicin—liver cancer	0.000129	0.00119	CcSEcCtD
Pemetrexed—Shock—Epirubicin—liver cancer	0.000127	0.00118	CcSEcCtD
Pemetrexed—Nervous system disorder—Epirubicin—liver cancer	0.000127	0.00118	CcSEcCtD
Pemetrexed—Thrombocytopenia—Epirubicin—liver cancer	0.000127	0.00117	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—liver cancer	0.000127	0.00117	CcSEcCtD
Pemetrexed—Skin disorder—Epirubicin—liver cancer	0.000126	0.00116	CcSEcCtD
Pemetrexed—Chest pain—Doxorubicin—liver cancer	0.000125	0.00116	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—liver cancer	0.000125	0.00116	CcSEcCtD
Pemetrexed—Myalgia—Doxorubicin—liver cancer	0.000125	0.00116	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000124	0.00115	CcSEcCtD
Pemetrexed—Anorexia—Epirubicin—liver cancer	0.000123	0.00114	CcSEcCtD
Pemetrexed—Oedema—Doxorubicin—liver cancer	0.00012	0.00111	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—liver cancer	0.00012	0.00111	CcSEcCtD
Pemetrexed—Infection—Doxorubicin—liver cancer	0.000119	0.0011	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000118	0.00109	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—liver cancer	0.000118	0.00109	CcSEcCtD
Pemetrexed—Nervous system disorder—Doxorubicin—liver cancer	0.000117	0.00109	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—liver cancer	0.000117	0.00109	CcSEcCtD
Pemetrexed—Skin disorder—Doxorubicin—liver cancer	0.000116	0.00108	CcSEcCtD
Pemetrexed—Dyspnoea—Epirubicin—liver cancer	0.000115	0.00107	CcSEcCtD
Pemetrexed—Anorexia—Doxorubicin—liver cancer	0.000114	0.00106	CcSEcCtD
Pemetrexed—Dyspepsia—Epirubicin—liver cancer	0.000114	0.00106	CcSEcCtD
Pemetrexed—Decreased appetite—Epirubicin—liver cancer	0.000112	0.00104	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Epirubicin—liver cancer	0.000112	0.00103	CcSEcCtD
Pemetrexed—Fatigue—Epirubicin—liver cancer	0.000112	0.00103	CcSEcCtD
Pemetrexed—Pain—Epirubicin—liver cancer	0.000111	0.00103	CcSEcCtD
Pemetrexed—Constipation—Epirubicin—liver cancer	0.000111	0.00103	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000109	0.00101	CcSEcCtD
Pemetrexed—Dyspnoea—Doxorubicin—liver cancer	0.000107	0.000989	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Epirubicin—liver cancer	0.000106	0.00098	CcSEcCtD
Pemetrexed—Dyspepsia—Doxorubicin—liver cancer	0.000105	0.000976	CcSEcCtD
Pemetrexed—Decreased appetite—Doxorubicin—liver cancer	0.000104	0.000964	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000103	0.000958	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—liver cancer	0.000103	0.000956	CcSEcCtD
Pemetrexed—Urticaria—Epirubicin—liver cancer	0.000103	0.000952	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—liver cancer	0.000102	0.000948	CcSEcCtD
Pemetrexed—Constipation—Doxorubicin—liver cancer	0.000102	0.000948	CcSEcCtD
Pemetrexed—Abdominal pain—Epirubicin—liver cancer	0.000102	0.000948	CcSEcCtD
Pemetrexed—Body temperature increased—Epirubicin—liver cancer	0.000102	0.000948	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Doxorubicin—liver cancer	9.79e-05	0.000907	CcSEcCtD
Pemetrexed—Hypersensitivity—Epirubicin—liver cancer	9.53e-05	0.000883	CcSEcCtD
Pemetrexed—Urticaria—Doxorubicin—liver cancer	9.51e-05	0.000881	CcSEcCtD
Pemetrexed—Abdominal pain—Doxorubicin—liver cancer	9.46e-05	0.000877	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—liver cancer	9.46e-05	0.000877	CcSEcCtD
Pemetrexed—Asthenia—Epirubicin—liver cancer	9.28e-05	0.00086	CcSEcCtD
Pemetrexed—Pruritus—Epirubicin—liver cancer	9.15e-05	0.000848	CcSEcCtD
Pemetrexed—Diarrhoea—Epirubicin—liver cancer	8.85e-05	0.00082	CcSEcCtD
Pemetrexed—Hypersensitivity—Doxorubicin—liver cancer	8.82e-05	0.000817	CcSEcCtD
Pemetrexed—Asthenia—Doxorubicin—liver cancer	8.59e-05	0.000796	CcSEcCtD
Pemetrexed—Dizziness—Epirubicin—liver cancer	8.56e-05	0.000793	CcSEcCtD
Pemetrexed—Pruritus—Doxorubicin—liver cancer	8.47e-05	0.000785	CcSEcCtD
Pemetrexed—Vomiting—Epirubicin—liver cancer	8.23e-05	0.000762	CcSEcCtD
Pemetrexed—Diarrhoea—Doxorubicin—liver cancer	8.19e-05	0.000759	CcSEcCtD
Pemetrexed—Rash—Epirubicin—liver cancer	8.16e-05	0.000756	CcSEcCtD
Pemetrexed—Dermatitis—Epirubicin—liver cancer	8.15e-05	0.000755	CcSEcCtD
Pemetrexed—Dizziness—Doxorubicin—liver cancer	7.92e-05	0.000733	CcSEcCtD
Pemetrexed—Nausea—Epirubicin—liver cancer	7.68e-05	0.000712	CcSEcCtD
Pemetrexed—Vomiting—Doxorubicin—liver cancer	7.61e-05	0.000705	CcSEcCtD
Pemetrexed—Rash—Doxorubicin—liver cancer	7.55e-05	0.000699	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—liver cancer	7.54e-05	0.000699	CcSEcCtD
Pemetrexed—Nausea—Doxorubicin—liver cancer	7.11e-05	0.000659	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—MYC—liver cancer	6.96e-05	0.00106	CbGpPWpGaD
Pemetrexed—DHFR—Disease—LTF—liver cancer	6.96e-05	0.00105	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PPARA—liver cancer	6.94e-05	0.00105	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTA3—liver cancer	6.87e-05	0.00104	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CYCS—liver cancer	6.85e-05	0.00104	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—liver cancer	6.85e-05	0.00104	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—PSMA4—liver cancer	6.8e-05	0.00103	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—PSMD10—liver cancer	6.8e-05	0.00103	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—SERPINE1—liver cancer	6.74e-05	0.00102	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GOT1—liver cancer	6.73e-05	0.00102	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GGT1—liver cancer	6.73e-05	0.00102	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—MYC—liver cancer	6.73e-05	0.00102	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—PPARA—liver cancer	6.35e-05	0.000962	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	6.34e-05	0.000961	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTA4—liver cancer	6.28e-05	0.000953	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—GOT1—liver cancer	6.26e-05	0.000948	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PSMD10—liver cancer	6.24e-05	0.000946	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PSMA4—liver cancer	6.24e-05	0.000946	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTA2—liver cancer	6.12e-05	0.000928	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GOT2—liver cancer	6.07e-05	0.00092	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GSTP1—liver cancer	6.04e-05	0.000916	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—HMOX1—liver cancer	5.96e-05	0.000903	CbGpPWpGaD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—ALB—liver cancer	5.95e-05	0.000902	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CG—liver cancer	5.95e-05	0.000901	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTA1—liver cancer	5.91e-05	0.000896	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—H2AFX—liver cancer	5.88e-05	0.000892	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—MYC—liver cancer	5.87e-05	0.000889	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—NAT2—liver cancer	5.84e-05	0.000886	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CPT1B—liver cancer	5.83e-05	0.000883	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GLUL—liver cancer	5.83e-05	0.000883	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	5.81e-05	0.000881	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PRKCE—liver cancer	5.77e-05	0.000875	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PPARG—liver cancer	5.74e-05	0.00087	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CYP2E1—liver cancer	5.71e-05	0.000865	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	5.69e-05	0.000863	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NR1H4—liver cancer	5.62e-05	0.000851	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ALDOB—liver cancer	5.6e-05	0.000849	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GSTM1—liver cancer	5.55e-05	0.000841	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	5.54e-05	0.00084	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	5.53e-05	0.000838	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTA3—liver cancer	5.52e-05	0.000837	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—PCNA—liver cancer	5.51e-05	0.000835	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	5.49e-05	0.000832	CbGpPWpGaD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—RAF1—liver cancer	5.38e-05	0.000816	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ALDOB—liver cancer	5.38e-05	0.000815	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	5.36e-05	0.000813	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CRABP1—liver cancer	5.34e-05	0.00081	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CYCS—liver cancer	5.34e-05	0.000809	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—JUN—liver cancer	5.31e-05	0.000805	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CYP1A1—liver cancer	5.26e-05	0.000798	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—H2AFX—liver cancer	5.26e-05	0.000797	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GGT1—liver cancer	5.24e-05	0.000794	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GOT1—liver cancer	5.24e-05	0.000794	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	5.23e-05	0.000793	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CD—liver cancer	5.23e-05	0.000792	CbGpPWpGaD
Pemetrexed—GART—Metabolism—ALB—liver cancer	5.16e-05	0.000782	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—H2AFX—liver cancer	5.13e-05	0.000778	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CPT1B—liver cancer	5.08e-05	0.00077	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GLUL—liver cancer	5.08e-05	0.00077	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTA4—liver cancer	5.05e-05	0.000765	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—H2AFX—liver cancer	5.03e-05	0.000763	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—MAPK8—liver cancer	5.02e-05	0.000761	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—PCNA—liver cancer	4.93e-05	0.000747	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTA2—liver cancer	4.92e-05	0.000746	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—MTHFR—liver cancer	4.91e-05	0.000744	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NR1H4—liver cancer	4.9e-05	0.000743	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	4.83e-05	0.000732	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTA3—liver cancer	4.82e-05	0.00073	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PPARA—liver cancer	4.81e-05	0.00073	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—PCNA—liver cancer	4.81e-05	0.000729	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TERT—liver cancer	4.76e-05	0.000721	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTA1—liver cancer	4.75e-05	0.00072	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—ALB—liver cancer	4.72e-05	0.000715	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GSTP1—liver cancer	4.71e-05	0.000713	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NAT2—liver cancer	4.7e-05	0.000712	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—HPGDS—liver cancer	4.67e-05	0.000708	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—HMOX1—liver cancer	4.64e-05	0.000703	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—H2AFX—liver cancer	4.59e-05	0.000696	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MTHFR—liver cancer	4.56e-05	0.000692	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CB—liver cancer	4.56e-05	0.000691	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TERT—liver cancer	4.55e-05	0.00069	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ALDOB—liver cancer	4.5e-05	0.000682	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	4.45e-05	0.000674	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	4.44e-05	0.000672	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTA4—liver cancer	4.41e-05	0.000668	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GSTM1—liver cancer	4.33e-05	0.000656	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—PCNA—liver cancer	4.3e-05	0.000651	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTA2—liver cancer	4.29e-05	0.000651	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CRABP1—liver cancer	4.29e-05	0.000651	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—RAF1—liver cancer	4.27e-05	0.000647	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ADAM17—liver cancer	4.25e-05	0.000644	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PSMA4—liver cancer	4.16e-05	0.000631	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PSMD10—liver cancer	4.16e-05	0.000631	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TERT—liver cancer	4.15e-05	0.000629	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTA1—liver cancer	4.14e-05	0.000628	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	4.14e-05	0.000628	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CG—liver cancer	4.12e-05	0.000625	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	4.11e-05	0.000623	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CYP1A1—liver cancer	4.1e-05	0.000621	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NAT2—liver cancer	4.1e-05	0.000621	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GOT2—liver cancer	4.05e-05	0.000614	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PSMD10—liver cancer	3.99e-05	0.000605	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PSMA4—liver cancer	3.99e-05	0.000605	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PPARG—liver cancer	3.98e-05	0.000603	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ALDOB—liver cancer	3.93e-05	0.000595	CbGpPWpGaD
Pemetrexed—DHFR—Disease—GOT2—liver cancer	3.89e-05	0.000589	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—APC—liver cancer	3.83e-05	0.000581	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—MTHFR—liver cancer	3.82e-05	0.000579	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP2E1—liver cancer	3.81e-05	0.000577	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	3.77e-05	0.000572	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—HPGDS—liver cancer	3.75e-05	0.000569	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PPARA—liver cancer	3.75e-05	0.000568	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CRABP1—liver cancer	3.75e-05	0.000568	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	3.65e-05	0.000553	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN2A—liver cancer	3.64e-05	0.000552	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CD—liver cancer	3.62e-05	0.000549	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—BRAF—liver cancer	3.6e-05	0.000546	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—ALB—liver cancer	3.58e-05	0.000542	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYCS—liver cancer	3.56e-05	0.00054	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—liver cancer	3.51e-05	0.000531	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GGT1—liver cancer	3.5e-05	0.00053	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GOT1—liver cancer	3.5e-05	0.00053	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CD—liver cancer	3.37e-05	0.000511	CbGpPWpGaD
Pemetrexed—DHFR—Disease—GOT1—liver cancer	3.35e-05	0.000508	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PSMA4—liver cancer	3.35e-05	0.000507	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PSMD10—liver cancer	3.35e-05	0.000507	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—SERPINE1—liver cancer	3.33e-05	0.000505	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—HPGDS—liver cancer	3.28e-05	0.000496	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GOT2—liver cancer	3.25e-05	0.000493	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN2A—liver cancer	3.25e-05	0.000493	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1B—liver cancer	3.22e-05	0.000489	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CG—liver cancer	3.21e-05	0.000487	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—IL6—liver cancer	3.21e-05	0.000486	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN2A—liver cancer	3.18e-05	0.000481	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CB—liver cancer	3.16e-05	0.000479	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTP1—liver cancer	3.14e-05	0.000476	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PPARG—liver cancer	3.1e-05	0.00047	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—HMOX1—liver cancer	3.1e-05	0.000469	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PRKCE—liver cancer	3.1e-05	0.000469	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	3.08e-05	0.000467	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—liver cancer	3.08e-05	0.000466	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP2E1—liver cancer	3.06e-05	0.000464	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—RAF1—liver cancer	3.01e-05	0.000456	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1A—liver cancer	2.97e-05	0.000451	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MTOR—liver cancer	2.94e-05	0.000445	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CB—liver cancer	2.94e-05	0.000445	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PSMA4—liver cancer	2.92e-05	0.000442	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PSMD10—liver cancer	2.92e-05	0.000442	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTM1—liver cancer	2.89e-05	0.000437	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1B—liver cancer	2.88e-05	0.000437	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYCS—liver cancer	2.86e-05	0.000434	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GOT2—liver cancer	2.84e-05	0.00043	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN2A—liver cancer	2.84e-05	0.00043	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CD—liver cancer	2.82e-05	0.000428	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1B—liver cancer	2.81e-05	0.000426	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GGT1—liver cancer	2.81e-05	0.000426	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GOT1—liver cancer	2.81e-05	0.000426	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ALB—liver cancer	2.79e-05	0.000422	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CA—liver cancer	2.78e-05	0.000421	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1B—liver cancer	2.76e-05	0.000418	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—liver cancer	2.75e-05	0.000417	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP1A1—liver cancer	2.74e-05	0.000415	CbGpPWpGaD
Pemetrexed—DHFR—Disease—H2AFX—liver cancer	2.7e-05	0.000409	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—liver cancer	2.68e-05	0.000407	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP2E1—liver cancer	2.67e-05	0.000405	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1A—liver cancer	2.66e-05	0.000403	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CTNNB1—liver cancer	2.61e-05	0.000395	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1A—liver cancer	2.6e-05	0.000393	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—MTHFR—liver cancer	2.55e-05	0.000387	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1A—liver cancer	2.54e-05	0.000386	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTP1—liver cancer	2.52e-05	0.000382	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1B—liver cancer	2.51e-05	0.000381	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PPARA—liver cancer	2.5e-05	0.000379	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYCS—liver cancer	2.5e-05	0.000379	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—HMOX1—liver cancer	2.49e-05	0.000377	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—liver cancer	2.47e-05	0.000374	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CB—liver cancer	2.46e-05	0.000373	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GGT1—liver cancer	2.45e-05	0.000372	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GOT1—liver cancer	2.45e-05	0.000372	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MTHFR—liver cancer	2.45e-05	0.000371	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TERT—liver cancer	2.44e-05	0.00037	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—liver cancer	2.4e-05	0.000364	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1A—liver cancer	2.32e-05	0.000352	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTM1—liver cancer	2.32e-05	0.000351	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—STAT3—liver cancer	2.27e-05	0.000344	CbGpPWpGaD
Pemetrexed—GART—Metabolism—AKT1—liver cancer	2.27e-05	0.000344	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—liver cancer	2.21e-05	0.000334	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTP1—liver cancer	2.2e-05	0.000334	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP1A1—liver cancer	2.2e-05	0.000333	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—HMOX1—liver cancer	2.17e-05	0.000329	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—liver cancer	2.15e-05	0.000326	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CG—liver cancer	2.14e-05	0.000325	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—liver cancer	2.11e-05	0.00032	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TGFB1—liver cancer	2.1e-05	0.000319	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PPARG—liver cancer	2.07e-05	0.000313	CbGpPWpGaD
Pemetrexed—DHFR—Disease—APC—liver cancer	2.06e-05	0.000312	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—MTHFR—liver cancer	2.05e-05	0.000311	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTM1—liver cancer	2.02e-05	0.000307	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PPARA—liver cancer	2.01e-05	0.000305	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KRAS—liver cancer	1.95e-05	0.000295	CbGpPWpGaD
Pemetrexed—DHFR—Disease—BRAF—liver cancer	1.93e-05	0.000293	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CA—liver cancer	1.93e-05	0.000292	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—liver cancer	1.92e-05	0.000292	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP1A1—liver cancer	1.92e-05	0.000291	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CD—liver cancer	1.88e-05	0.000285	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ALB—liver cancer	1.86e-05	0.000282	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—liver cancer	1.81e-05	0.000275	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CD—liver cancer	1.81e-05	0.000274	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CA—liver cancer	1.79e-05	0.000271	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—MTHFR—liver cancer	1.79e-05	0.000271	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SERPINE1—liver cancer	1.79e-05	0.000271	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PPARA—liver cancer	1.75e-05	0.000266	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CG—liver cancer	1.72e-05	0.000261	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PPARG—liver cancer	1.66e-05	0.000252	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HRAS—liver cancer	1.66e-05	0.000251	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CB—liver cancer	1.64e-05	0.000249	CbGpPWpGaD
Pemetrexed—DHFR—Disease—RAF1—liver cancer	1.61e-05	0.000245	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—IL6—liver cancer	1.59e-05	0.00024	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—liver cancer	1.58e-05	0.00024	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MTOR—liver cancer	1.58e-05	0.000239	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CB—liver cancer	1.58e-05	0.000239	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—AKT1—liver cancer	1.57e-05	0.000238	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CD—liver cancer	1.51e-05	0.000229	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CG—liver cancer	1.5e-05	0.000228	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CA—liver cancer	1.5e-05	0.000227	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ALB—liver cancer	1.49e-05	0.000226	CbGpPWpGaD
Pemetrexed—ATIC—embryo—liver cancer	1.48e-05	0.195	CbGeAlD
Pemetrexed—DHFR—Disease—CDKN1B—liver cancer	1.48e-05	0.000224	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—AKT1—liver cancer	1.46e-05	0.000222	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PPARG—liver cancer	1.45e-05	0.00022	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CTNNB1—liver cancer	1.4e-05	0.000212	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1A—liver cancer	1.36e-05	0.000207	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CD—liver cancer	1.32e-05	0.0002	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CB—liver cancer	1.32e-05	0.0002	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ALB—liver cancer	1.3e-05	0.000198	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—AKT1—liver cancer	1.23e-05	0.000186	CbGpPWpGaD
Pemetrexed—DHFR—Disease—STAT3—liver cancer	1.22e-05	0.000185	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CB—liver cancer	1.15e-05	0.000174	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—liver cancer	1.13e-05	0.000171	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TGFB1—liver cancer	1.13e-05	0.000171	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KRAS—liver cancer	1.05e-05	0.000158	CbGpPWpGaD
Pemetrexed—GART—liver—liver cancer	1.01e-05	0.133	CbGeAlD
Pemetrexed—DCK—Metabolism—PIK3CA—liver cancer	1e-05	0.000152	CbGpPWpGaD
Pemetrexed—DHFR—embryo—liver cancer	9.93e-06	0.131	CbGeAlD
Pemetrexed—DHFR—Disease—PIK3CA—liver cancer	9.6e-06	0.000146	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HRAS—liver cancer	8.89e-06	0.000135	CbGpPWpGaD
Pemetrexed—DCK—embryo—liver cancer	8.59e-06	0.113	CbGeAlD
Pemetrexed—DHFR—Disease—IL6—liver cancer	8.5e-06	0.000129	CbGpPWpGaD
Pemetrexed—SLC46A1—liver—liver cancer	8.18e-06	0.108	CbGeAlD
Pemetrexed—DCK—Metabolism—AKT1—liver cancer	8.18e-06	0.000124	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CA—liver cancer	8.04e-06	0.000122	CbGpPWpGaD
Pemetrexed—DHFR—Disease—AKT1—liver cancer	7.85e-06	0.000119	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CA—liver cancer	7.02e-06	0.000106	CbGpPWpGaD
Pemetrexed—ATIC—liver—liver cancer	6.84e-06	0.0903	CbGeAlD
Pemetrexed—DHFR—Metabolism—AKT1—liver cancer	6.57e-06	9.96e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—AKT1—liver cancer	5.73e-06	8.69e-05	CbGpPWpGaD
Pemetrexed—TYMS—liver—liver cancer	4.64e-06	0.0612	CbGeAlD
Pemetrexed—DHFR—liver—liver cancer	4.59e-06	0.0606	CbGeAlD
Pemetrexed—SLC29A1—liver—liver cancer	4.16e-06	0.0549	CbGeAlD
Pemetrexed—DCK—liver—liver cancer	3.97e-06	0.0525	CbGeAlD
